Return to Article Details Do you believe that N-of-1 trials (a clinical trial in which a single patient is the entire trial), are appropriate to evaluate the effectiveness of genomic therapies for rare and/or common genetic disorders? Do gene-editing/targeting therapies have the potential to expedite the advancement of personalized medicine?